Src family kinases differentially influence glioma growth and motility

Laura J. Lewis-Tuffin, Ryan Feathers, Priya Hari, Nisha Durand, Zhimin Li, Fausto J. Rodriguez, Katie Bakken, Brett Carlson, Mark Schroeder, Jann N. Sarkaria, Panos Z. Anastasiadis

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


Src-family kinase (SFK) signaling impacts multiple tumor-related properties, particularly in the context of the brain tumor glioblastoma. Consequently, the pan-SFK inhibitor dasatinib has emerged as a therapeutic strategy, despite physiologic limitations to its effectiveness in the brain. We investigated the importance of individual SFKs (Src, Fyn, Yes, and Lyn) to glioma tumor biology by knocking down individual SFK expression both in culture (LN229, SF767, GBM8) and orthotopic xenograft (GBM8) contexts. We evaluated the effects of these knockdowns on tumor cell proliferation, migration, and motility-related signaling in culture, as well as overall survival in the orthotopic xenograft model. The four SFKs differed significantly in their importance to these properties. In culture, Src, Fyn, and Yes knockdown generally reduced growth and migration and altered motility-related phosphorylation patterns while Lyn knockdown did so to a lesser extent. However the details of these effects varied significantly depending on the cell line: in no case were conclusions about the role of a particular SFK applicable to all of the measures or all of the cell types examined. In the orthotopic xenograft model, mice implanted with non-target or Src or Fyn knockdown cells showed no differences in survival. In contrast, mice implanted with Yes knockdown cells had longer survival, associated with reduced tumor cell proliferation. Those implanted with Lyn knockdown cells had shorter survival, associated with higher overall tumor burden. Together, our results suggest that Yes signaling directly affects tumor cell biology in a pro-tumorigenic manner, while Lyn signaling affects interactions between tumor cells and the microenvironment in an anti-tumor manner. In the context of therapeutic targeting of SFKs, these results suggest that pan-SFK inhibitors may not produce the intended therapeutic benefit when Lyn is present.

Original languageEnglish (US)
Pages (from-to)1783-1798
Number of pages16
JournalMolecular Oncology
Issue number9
StatePublished - Nov 2015


  • Dasatinib
  • Glioblastoma
  • Lyn kinase
  • Migration
  • Proliferation
  • Src-family kinase

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Oncology
  • Cancer Research


Dive into the research topics of 'Src family kinases differentially influence glioma growth and motility'. Together they form a unique fingerprint.

Cite this